Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | F10 | P00742 | 5/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9611225 | 1.00 | ALDH1A1 (0.36) | ALDH1A1NPSR1F10ATMLMNA | |
| SCHEMBL12164497 | 1.00 | ALDH1A1 (0.36) | ALDH1A1NPSR1F10ATMLMNA | |
| SCHEMBL3429780 | 1.00 | ALDH1A1 (0.36) | ALDH1A1NPSR1F10ATMLMNA | |
| SCHEMBL30545409 | 0.84 | F10 (0.36) | ALDH1A1F10ATMLMNAPOLB | |
| SCHEMBL1412659 | 0.80 | ALDH1A1 (0.37) | ALDH1A1NPSR1ATMLMNAPOLB | |
| SCHEMBL14312213 | 0.80 | ALDH1A1 (0.37) | ALDH1A1NPSR1ATMLMNAPOLB | |
| SCHEMBL14312248 | 0.80 | ALDH1A1 (0.37) | ALDH1A1NPSR1ATMLMNAPOLB | |
| SCHEMBL15483710 | 0.79 | CYP3A4 (0.35) | ALDH1A1NPSR1ATMLMNAPOLB | |
| SCHEMBL3281207 | 0.79 | CYP3A4 (0.35) | ALDH1A1NPSR1ATMLMNAPOLB | |
| SCHEMBL8434138 | 0.79 | CYP3A4 (0.35) | ALDH1A1NPSR1ATMLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | ARRAY BIOPHARMA, INC. (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208995-A1 | NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION | EIF2AK2, HAVCR2, HCCS | ALDH1A1 2539/4885NPSR1 4812/4885F10 2678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.